Last Price
149.86
Today's Change
-6.37 (4.07%)
Day's Change
149.86 - 149.86
Trading Volume
3
Overview
Market Cap
31 Billion
Shares Outstanding
213 Million
Avg Volume
1,364
Avg Price (50 Days)
28.37
Avg Price (200 Days)
24.95
PE Ratio
-39.68
EPS
-3.78
Earnings Announcement
19-Feb-2026
Previous Close
156.23
Open
149.86
Day's Range
149.86 - 149.86
Year Range
16.585 - 149.86
Trading Volume
3
Price Change Highlight
1 Day Change
-4.08%
5 Day Change
-6.92%
1 Month Change
-14.98%
3 Month Change
-18.68%
6 Month Change
37.78%
Ytd Change
-14.55%
1 Year Change
94.93%
3 Year Change
640.78%
5 Year Change
283.27%
10 Year Change
416.76%
Max Change
416.76%
News and Blogs
No result.
Company Profile
Sector: Healthcare - Healthcare
Industry: Pharmaceuticals, Biotechnology & Life Sciences
Description:
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Discussions
Be the first to like this.
Showing 0 of 0 comments
Post a Comment
Latest Videos
![[New IPO] Hock Soon Capital Berhad, a leading Malaysian egg producer, expands to meet growing local and regional demand, plans to list on the Main Market!](https://mqac.i3investor.com/img/video_thumbnail/1419/Thumbnail__(25).png)
Apps
Top Articles
1
Stumbling and Mumbling
Daily Stocks
Stock
Last
Change
Volume
Stock
Last
Change
Volume
Stock
Last
Change
Volume
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
{uid}
{comment}
Just now